Optimization of donor specific blood transfusion in kidney transplantation.

J. S. Cheigh, Manikkam Suthanthiran, W. T. Stubenbord, M. Fotino, R. R. Riggio, N. Schechter, K. H. Stenzel, A. L. Rubin

Research output: Contribution to journalArticle

Abstract

1. One hundred milliliters of stored whole blood DST, three times at weekly intervals is a practical, less immunizing and effective approach to enhance graft survival in recipients of a living-related donor kidney. 2. This protocol could also be used in sibling donor/recipient pairs who do not share a haplotype as well as in those who share two haplotypes to enhance graft survival. 3. The use of a short course of Cs (6 mg/kg/d for three weeks) along with DST appears to reduce the sensitization rate even lower. The dose of Cs used in this study produced no clinically significant adverse reactions, whereas Aza (1 mg/kg/d) often produces leukopenia. 4. DST produces significantly suppressed donor specific MLC responses in the early post-DST period; however, it increases the response at a later time. DST modulates immune responses in such a way that secondary responses upon grafting are more readily reversible by immunosuppressive agents.

Original languageEnglish
Pages (from-to)2250-2251
Number of pages2
JournalTransplantation Proceedings
Volume19
Issue number1 Pt 3
Publication statusPublished - 1 Feb 1987
Externally publishedYes

Fingerprint

Graft Survival
Blood Transfusion
Kidney Transplantation
Haplotypes
Tissue Donors
Living Donors
Leukopenia
Immunosuppressive Agents
Siblings
Kidney
caN protocol

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Cheigh, J. S., Suthanthiran, M., Stubenbord, W. T., Fotino, M., Riggio, R. R., Schechter, N., ... Rubin, A. L. (1987). Optimization of donor specific blood transfusion in kidney transplantation. Transplantation Proceedings, 19(1 Pt 3), 2250-2251.

Optimization of donor specific blood transfusion in kidney transplantation. / Cheigh, J. S.; Suthanthiran, Manikkam; Stubenbord, W. T.; Fotino, M.; Riggio, R. R.; Schechter, N.; Stenzel, K. H.; Rubin, A. L.

In: Transplantation Proceedings, Vol. 19, No. 1 Pt 3, 01.02.1987, p. 2250-2251.

Research output: Contribution to journalArticle

Cheigh, JS, Suthanthiran, M, Stubenbord, WT, Fotino, M, Riggio, RR, Schechter, N, Stenzel, KH & Rubin, AL 1987, 'Optimization of donor specific blood transfusion in kidney transplantation.', Transplantation Proceedings, vol. 19, no. 1 Pt 3, pp. 2250-2251.
Cheigh JS, Suthanthiran M, Stubenbord WT, Fotino M, Riggio RR, Schechter N et al. Optimization of donor specific blood transfusion in kidney transplantation. Transplantation Proceedings. 1987 Feb 1;19(1 Pt 3):2250-2251.
Cheigh, J. S. ; Suthanthiran, Manikkam ; Stubenbord, W. T. ; Fotino, M. ; Riggio, R. R. ; Schechter, N. ; Stenzel, K. H. ; Rubin, A. L. / Optimization of donor specific blood transfusion in kidney transplantation. In: Transplantation Proceedings. 1987 ; Vol. 19, No. 1 Pt 3. pp. 2250-2251.
@article{41ed034d6b9341fe99eea3fe357d20c5,
title = "Optimization of donor specific blood transfusion in kidney transplantation.",
abstract = "1. One hundred milliliters of stored whole blood DST, three times at weekly intervals is a practical, less immunizing and effective approach to enhance graft survival in recipients of a living-related donor kidney. 2. This protocol could also be used in sibling donor/recipient pairs who do not share a haplotype as well as in those who share two haplotypes to enhance graft survival. 3. The use of a short course of Cs (6 mg/kg/d for three weeks) along with DST appears to reduce the sensitization rate even lower. The dose of Cs used in this study produced no clinically significant adverse reactions, whereas Aza (1 mg/kg/d) often produces leukopenia. 4. DST produces significantly suppressed donor specific MLC responses in the early post-DST period; however, it increases the response at a later time. DST modulates immune responses in such a way that secondary responses upon grafting are more readily reversible by immunosuppressive agents.",
author = "Cheigh, {J. S.} and Manikkam Suthanthiran and Stubenbord, {W. T.} and M. Fotino and Riggio, {R. R.} and N. Schechter and Stenzel, {K. H.} and Rubin, {A. L.}",
year = "1987",
month = "2",
day = "1",
language = "English",
volume = "19",
pages = "2250--2251",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1 Pt 3",

}

TY - JOUR

T1 - Optimization of donor specific blood transfusion in kidney transplantation.

AU - Cheigh, J. S.

AU - Suthanthiran, Manikkam

AU - Stubenbord, W. T.

AU - Fotino, M.

AU - Riggio, R. R.

AU - Schechter, N.

AU - Stenzel, K. H.

AU - Rubin, A. L.

PY - 1987/2/1

Y1 - 1987/2/1

N2 - 1. One hundred milliliters of stored whole blood DST, three times at weekly intervals is a practical, less immunizing and effective approach to enhance graft survival in recipients of a living-related donor kidney. 2. This protocol could also be used in sibling donor/recipient pairs who do not share a haplotype as well as in those who share two haplotypes to enhance graft survival. 3. The use of a short course of Cs (6 mg/kg/d for three weeks) along with DST appears to reduce the sensitization rate even lower. The dose of Cs used in this study produced no clinically significant adverse reactions, whereas Aza (1 mg/kg/d) often produces leukopenia. 4. DST produces significantly suppressed donor specific MLC responses in the early post-DST period; however, it increases the response at a later time. DST modulates immune responses in such a way that secondary responses upon grafting are more readily reversible by immunosuppressive agents.

AB - 1. One hundred milliliters of stored whole blood DST, three times at weekly intervals is a practical, less immunizing and effective approach to enhance graft survival in recipients of a living-related donor kidney. 2. This protocol could also be used in sibling donor/recipient pairs who do not share a haplotype as well as in those who share two haplotypes to enhance graft survival. 3. The use of a short course of Cs (6 mg/kg/d for three weeks) along with DST appears to reduce the sensitization rate even lower. The dose of Cs used in this study produced no clinically significant adverse reactions, whereas Aza (1 mg/kg/d) often produces leukopenia. 4. DST produces significantly suppressed donor specific MLC responses in the early post-DST period; however, it increases the response at a later time. DST modulates immune responses in such a way that secondary responses upon grafting are more readily reversible by immunosuppressive agents.

UR - http://www.scopus.com/inward/record.url?scp=0023281564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023281564&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 2250

EP - 2251

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1 Pt 3

ER -